About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
When combined with potent antiplatelet agents and low-molecular-weight heparins, tenecteplase has demonstrated improved patient outcomes.
Gordon J. Vanscoy, PharmD, CACP, MBA, Thomas L. Rihn, PharmD, and Pamela H. Koerner, PharmD
The author reviews vaccine studies, combination rituximab trials, and developments with antisense therapy, proteosome inhibitors, and promising monoclonal antibodies.
Marvin M. Goldenberg, PhD, RPh, MS
Using a unit-specific pharmacist allows smaller hospitals to focus on patient care with greater flexibility and minimal increases in staffing.
Jeffrey G. Santorello, MS, RPh, Olga Larios, MS, RPh, and Joseph Dougherty, RPh
Editor-in-Chief David Nash explains how public disclosure of health plan performance can “turn errors into gold.”
David B. Nash, MD, MBA
Mr. Grissinger discusses how failure mode and effects analysis can help guide error-prevention efforts.
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Mr. Barlas questions the veracity of some direct-to-consumer drug ads.
The authors review a new agent, adefovir dipivoxil, for the treatment of active hepatitis B virus infection.
Tarrah Williams, PharmD Candidate, Marlon Honeywell, PharmD, Evans Branch III, PharmD, and Frank Emanuel, PharmD
A review of six years of hospital data shows a steady increase in the use of aspirin, antiplatelets, and beta blockers.